Drug and nutrition interactions: Not just food for thought

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 4, 2013, Pages 269-271

  Boullata, J I ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

drug interactions; food; nutrient; nutrition; safety

Indexed keywords

ATORVASTATIN; BIOTIN; CALCIUM; CAPECITABINE; CARBAMAZEPINE; CIPROFLOXACIN; ERTAPENEM; LEVODOPA; QUETIAPINE; VITAMIN D;

BODY SURFACE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PENETRATION; DRUG RESPONSE; DRUG SOLUBILITY; FOOD DRUG INTERACTION; HUMAN; HYPERTRIGLYCERIDEMIA; NUTRIENT; NUTRITIONAL STATUS; OBESITY; PATIENT CARE; REVIEW; WEIGHT GAIN;

DRUG INTERACTIONS; FOOD; NUTRIENT; NUTRITION; SAFETY;

FOOD; FOOD-DRUG INTERACTIONS; HUMANS; NUTRITIONAL STATUS; PHARMACEUTICAL PREPARATIONS;

EID: 84879898204     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12075     Document Type: Review

References (42)

1. Santos CA, Boullata JI,. An approach to evaluating drug-nutrient interactions. Pharmacotherapy, 2005; 25: 1789-1800.
2. Boullata JI,. An introduction to drug-nutrient interactions. In:, Boullata JI, Armenti VT, eds. Handbook of drug-nutrient interactions. 2nd edn. New York, NY: Humana Press; 3-26, 2010.
3. Welling PG,. Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm, 1977; 5: 291-334.
4. Said HM, Redha R, Nylander W,. Biotin transport in the human intestine: inhibition by anticonvulsant drugs. Am J Clin Nutr, 1989; 49: 127-131.
5. Mock DM, Dyken ME,. Biotin catabolism is accelerated in adults receiving long-term therapy with anticonvulsants. Neurology, 1997; 49: 1444-1447.
6. Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS,. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother, 2006; 50: 1222-1227.
7. Kurt M, Babaoglu MO, Yasar U, Shorbagi A, Guler N,. Capecitabine-induced severe hypertriglyceridemia: report of two cases. Ann Pharmacother, 2006; 40: 328-331.
8. Schwartz JB,. Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther, 2009; 85: 198-203.
9. Williams SG, Alinejad NA, Williams JA, Cruess DF,. Statistically significant increase in weight caused by low-dose quetiapine. Pharmacotherapy, 2010; 30: 1011-1015.
10. Boullata JI, Hudson LM,. Drug-nutrient interactions: a broad view with implications for practice. J Acad Nutr Diet, 2012; 112: 506-517.
11. Biehl JP, Vilter RW,. Effects of isoniazid on pyridoxine metabolism. JAMA, 1954; 156: 1549-1552.
12. Neovonen P, Gothoni G, Hackman R, Bjorksten K,. Interference of iron with the absorption of tetracyclines in man. BMJ, 1970; 4: 532-534.
13. Krishnaswamy K,. Drug metabolism and pharmacokinetics in malnutrition. Clin Pharmacokinet, 1978; 3: 216-240.
14. Roe DA,. Drug effects on nutrient absorption, transport, and metabolism. Drug Nutr Interact, 1985; 4: 117-135.
15. Chan L-N,. Drug-nutrient interactions in clinical nutrition. Curr Opin Clin Nutr Metab Care, 2002; 5: 327-332.
16. Mason P,. Important drug-nutrient interactions. Proceed Nutr Soc, 2010; 69: 551-557.
17. Fleisher D, Sweet BV, Parekh A, Boullata JI,. Drug absorption with food. In:, Boullata JI, Armenti VT, eds. Handbook of drug-nutrient interactions. 2nd edn. New York, NY: Humana Press, 209-241, 2010.
18. Bailey DG,. Grapefruit and other fruit juices interactions with medicines. In:, Boullata JI, Armenti VT, eds. Handbook of drug-nutrient interactions. 2nd edn. New York, NY: Humana Press, 267-302, 2010.
19. Ando H, Tsuruoka S, Yanagihara H, et al,. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol, 2005; 60: 494-497.
20. Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al,. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther, 2002; 71: 21-29.
21. Glaeser H, Bailey DG, Dresser GK, et al,. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther, 2007; 81: 362-370.
22. Lilja JJ, Laitinen K, Neuvonen PJ,. Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol, 2005; 60: 337-341.
23. Dolton MJ, Roufogalis BD, McLachlan AJ,. Fruit juices as perpetrators of drug interactions: the role of organic anion-transporting polypeptides. Clin Pharmacol Ther, 2012; 92: 622-630.
24. Peng CC, Glassman PA, Trilli LE, et al,. Incidence and severity of potential drug-dietary supplement interactions in primary care patients: an exploratory study of 2 outpatient practices. Arch Intern Med, 2004; 164: 630-636.
25. Lee AH, Ingraham SE, Kopp M, et al,. The incidence of potential interactions between dietary supplements and prescription medications in cancer patients at a Veterans Administration hospital. Am J Clin Oncol, 2006; 29: 178-182.
26. Sood A, Sood R, Brinker FJ, et al,. Potential for interactions between dietary supplements and prescription medications. Am J Med, 2008; 121: 207-211.
27. Loya AM, González-Stuart A, Rivera JO,. Prevalence of polypharmacy, polyherbacy, nutritional supplement use and potential product interactions among older adults living on the United States-Mexico border: a descriptive, questionnaire-based study. Drugs Aging, 2009; 26: 423-436.
28. Egert S, Rimbach G,. Which sources of flavonoids: complex diets or dietary supplements? Adv Nutr, 2011; 2: 8-14.
29. Gurley BJ., Pharmacokinetic herb-drug interactions (part 1): origins, mechanisms, and the impact of botanical dietary supplements. Planta Med, 2012; 78: 1478-1489.
30. Gurley BJ, Fifer EK, Gardner Z., Pharmacokinetic herb-drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Med, 2012; 78: 1490-1514.
31. Boullata JI,. Drug disposition in obesity and protein-energy malnutrition. Proceed Nutr Soc, 2010; 69: 543-550.
32. Jacques KA, Erstad BL,. Availability of information for dosing injectable medications in underweight or obese patients. Am J Health-Syst Pharm, 2010; 67: 1948-1950.
33. Pai MP,. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy, 2012; 32: 856-868.
34. Janmahasatian S, Duffull SB, Ash S, et al,. Quantification of lean body-weight. Clin Pharmacokinet, 2005; 44: 1051-1065.
35. White R,. Drugs and nutrition: how side effects can influence nutritional intake. Proceed Nutr Soc, 2010; 69: 558-564.
36. Lombardi LR, Kreys E, Gerry S, Boullata JI,. Nutrition in the age of polypharmacy. In:, Bendich A, Deckelbaum RJ, eds. Preventive nutrition, 4th edn. New York, NY: Humana Press, 79-125, 2010.
37. Zadak Z, Hyspler R, Ticha A, Vlcek J,. Polypharmacy and malnutrition. Curr Opin Clin Nutr Metab Care, 2013; 16: 50-55.
38. Pascussi JM, Robert A, Nguyen M, et al,. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest, 2005; 115: 177-186.
39. Oscarson M, Zanger UM, Rifki OF, et al,. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther, 2006; 80: 440-456.
40. Xu Y, Hashizume T, Shuhart MC, et al,. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1α25-dihydroxyvitamin D3: implications for drug-induced osteomalacia. Mol Pharmacol, 2006; 69: 56-65.
41. Van Wouwe JP,. Carnitine deficiency during valproic acid treatment. Int J Vit Nutr Res, 1995; 65: 211-214.
42. Werner T, Treiss I, Kohlmueller D, et al,. Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS. Epilepsia, 2007; 48: 72-76.